摘要
目的:探讨酒石酸罗格列酮(噻唑烷二酮类药物)抑制动脉粥样硬化的作用。方法:60例2型糖尿病患者服用罗格列酮4mg/d,观察期3个月。通过B型超声仪检测治疗前后颈动脉内膜中层厚度(IMT)及相关生化指标的变化。结果:患者服用罗格列酮3个月后,其IMT值(0.78±0.14)同治疗前(0.84±0.14)比较明显的降低(P<0.001),且IMT值与胰岛素抵抗指数(IAI)呈正相关(r=0.31,P<0.05)。结论:酒石酸罗格列酮可能通过降低胰岛素抵抗以及发挥抗炎抗细胞增殖作用,对2型糖尿病早期动脉粥样硬化病变具有一定的抑制作用。
Objective. To investigate the antiatherogenic actions of rosiglitazone. Methods Rosiglitazone （4 mg daily）was administered for 60 subjects with Type 2 diabetes. The changes of IMT and some relative indexes before and after the treatment were compared by B-mode ultrasound. Results： Rosiglitazone showed a significant decrease in IMT （0.78±0.14） as early as it was （0.84±0.14） 3 months after the administration （P〈0.001）,and IMT was positively associated with IAI （r=0.31, P〈0.05）. Conclusion： These results indicate that rosiglitazone cause an inhibition of early atherosclerotic processs maybe through the decreased insulin resistance,anti-inflammation and anti-proliferation actions in type 2 diabetes.
出处
《天津医科大学学报》
2006年第1期62-64,共3页
Journal of Tianjin Medical University
关键词
噻唑烷二酮
2型糖尿病
颈动脉内膜中层厚度
胰岛素抵抗
Thiazolidinediones
Type 2 diabetes
Common carotid arterial inimal and medialcomples thickenss
Insulin resistance
